Who are DAPA/MET XR's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Janagliflozin plus metformin.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/dapa-met-xr.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

DAPA/MET XR — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

DAPA/MET XR (DAPA/MET XR) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: SGLT2 inhibitor + biguanide combination. Area: Diabetes.

phase 3 SGLT2 inhibitor + biguanide combination SGLT2; metformin (mitochondrial complex I) Diabetes Small molecule Live · refreshed every 30 min

Target snapshot

DAPA/MET XR (DAPA/MET XR) — Woman's. DAPA/MET XR is a fixed-dose combination of dapagliflozin (SGLT2 inhibitor) and metformin extended-release that lowers blood glucose by increasing urinary glucose excretion and reducing hepatic glucose production.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
DAPA/MET XR TARGET	DAPA/MET XR	Woman's	phase 3	SGLT2 inhibitor + biguanide combination	SGLT2; metformin (mitochondrial complex I)
Janagliflozin plus metformin	Janagliflozin plus metformin	Sihuan Pharmaceutical Holdings Group Ltd.	phase 3	SGLT2 inhibitor + biguanide combination	SGLT2; metformin (mitochondrial complex I)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (SGLT2 inhibitor + biguanide combination class)

Sihuan Pharmaceutical Holdings Group Ltd. · 1 drug in this class
Woman's · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). DAPA/MET XR — Competitive Intelligence Brief. https://druglandscape.com/ci/dapa-met-xr. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab